Rabeprazole Sodium 20mg & Levosulpiride 75mg Capsules (Sustained Release Pellets) — Capsules
WHO-GMP Certified Commercial Pack · Product Code: AKP-015

Rabeprazole Sodium 20mg & Levosulpiride 75mg Capsules (Sustained Release Pellets)

Formulation Overview: Advanced prokinetic-PPI capsule pairing enteric-coated rabeprazole with sustained-release levosulpiride 75 mg to enhance lower esophageal sphincter tone and accelerate antroduodenal coordination. Formulated with Rabeprazole Sodium IP 20 mg (EC) + Levosulpiride 75 mg (SR Pellets) (20 mg + 75 mg (SR)) in Sustained-Release Pellet Capsules dosage form under Gastroenterology & PPIs, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
Item Code (SKU)AKP-015
Therapeutic SectorGastroenterology & PPIs
Dosage FormSustained-Release Pellet Capsules
Active IngredientRabeprazole Sodium IP 20 mg (EC) + Levosulpiride 75 mg (SR Pellets)
Strength / Purity20 mg + 75 mg (SR)
Clinical IndicationRefractory GERD, diabetic gastroparesis, and irritable bowel-associated upper dyspepsia
Specification StandardIP / BP / USP Compendial
Packaging Format10 x 10 Alu-Alu Blister Pack
Shelf Life24–36 Months
Storage ConditionsStore below 25°C, protect from moisture & direct sunlight
Minimum Order Quantity1000 Packs
Regulatory / Analytical DocsFull eCTD / ACTD Modules 1–5 + Zone IVb Stability Available
African & Global NRA ReadinessNAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA
Stock AvailabilityIn Stock · Immediate Commercial Dispatch
Supply StatusCommercial Export Ready

Related Capsules & Gastroenterology & PPIs